Co-Authors
This is a "connection" page, showing publications co-authored by Peter Friedmann and Elizabeth Evans.
Connection Strength
5.553
-
Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Dec; 122:104252.
Score: 0.910
-
Friedmann PD, Dunn D, Michener P, Bernson D, Stopka TJ, Pivovarova E, Ferguson WJ, Rottapel R, Hoskinson R, Wilson D, Evans EA. COVID-19 impact on opioid overdose after jail release in Massachusetts. Drug Alcohol Depend Rep. 2023 Mar; 6:100141.
Score: 0.866
-
Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat. 2022 07; 138:108746.
Score: 0.807
-
Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
Score: 0.802
-
Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.
Score: 0.245
-
Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.
Score: 0.241
-
Michener PS, Bianchet E, Fox S, Evans EA, Friedmann PD. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder. Harm Reduct J. 2024 07 22; 21(1):138.
Score: 0.239
-
Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024 02 12; 19(1):10.
Score: 0.231
-
Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, Friedmann PD. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022 11; 109:103823.
Score: 0.209
-
Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Int J Drug Policy. 2022 Dec; 110:103803.
Score: 0.208
-
Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022 05 01; 234:109394.
Score: 0.202
-
Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
Score: 0.187
-
Friedmann PD, Abraham A, Evans E, Glass J, Ilgen M, Montgomery L. Editorial: COVID-19 and its impact on SUD treatment. J Subst Abuse Treat. 2020 10; 117:108091.
Score: 0.181
-
Ryan D, Ekanayake DL, Evans E, Hayes E, Senst T, Friedmann PD, McCollister KE, Murphy SM. Cost analysis of MOUD implementation and sustainability in Massachusetts jails. Health Justice. 2025 Feb 05; 13(1):9.
Score: 0.062
-
Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
Score: 0.060
-
Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
Score: 0.058
-
Montgomery L, Friedmann P, Abraham A, Evans E, Glass J, Ilgen M. Editorial: Health equity in substance use disorder treatment. J Subst Abuse Treat. 2020 11; 118:108101.
Score: 0.045